Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences.

Tech stocks are bouncing back Monday after last week's selloff, which was fueled by growing investor concerns over massive AI infrastructure spending. Several big-name tech stocks are sitting out the ...

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...

Ethos (Nasdaq: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the third quarter ended September 30, ...

Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard Time. Upon closing, ...